In Reply to Pe ñagarícano

Thank you for your comments1 regarding our manuscript “Pulsed reduced dose rate radiation therapy in conjunction with bevacizumab significantly extends survival over bevacizumab alone in recurrent high-grade glioma.”2 We agree there is mounting evidence supporting the notion that dose rate is an important variable that impacts radiosensitivity and normal tissue tolerance in the irradiation of primary brain tumors and potentially other tumor types.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comments Source Type: research